Transfusionsmedizin 2024; 14(02): 95-108
DOI: 10.1055/a-2138-6321
CME-Fortbildung

Nachweis thrombozytärer Antikörper – aktueller Stand

Current state of platelet antibody detection
Volker Kiefel

Thrombozyten spielen eine besondere Rolle bei der Blutstillung. Viele Ursachen können die Leistungsfähigkeit des thrombozytären Systems beeinträchtigen, vor allem Zustände mit einer verminderten Zahl von Thrombozyten. Antikörper gegen Thrombozyten sind für einen Teil der Fälle von Thrombozytopenie verantwortlich, sie können darüber hinaus die Wirksamkeit von Thrombozytentransfusionen beeinträchtigen. Daher spielen Methoden zum Nachweis thrombozytärer Antikörper bei der Diagnose und der Behandlung von thrombozytopenischen Zuständen eine Rolle. Relativ hohe Kosten und Aufwand erfordern eine fachlich gut begründete Indikationsstellung bei Kenntnis des klinischen Hintergrunds.

Abstract

Platelets play a central role in hemostasis. Various conditions may interfere with platelet action: among the most important are processes resulting in thrombocytopenia. In a subset of affected patients thrombocytopenia is induced by platelet antibodies. Platelet antibodies are involved in autoimmune thrombocytopenia, materno-fetal incompatibility and transfusion reactions. Platelet reactive antibodies may also reduce the efficacy of platelet transfusions. Therefore, laboratory techniques play a crucial role in diagnosis and therapy of thrombocytopenic states. As high-quality laboratory diagnostics is limited and rather expensive, physicians should have a good knowledge of the clinical and pathophysiological background. Readers of this article will be able to understand the principle of platelet antibody immunoassays and will be qualified to order these analyses and to assess their results.



Publikationsverlauf

Artikel online veröffentlicht:
08. Mai 2024

© 2024. Thieme. All rights reserved.

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 
  • Literatur

  • 1 Twilfert M, Sümnig A, Bakchoul T. et al Prevalence of platelet alloantibodies in female blood donors with previous pregnancies. Transfus Med Hemother 2014; 41 29 doi:
  • 2 Ertel K, Al-Tawil M, Santoso S. et al. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. Transfusion 2005; 45: 366-373
  • 3 Ohto H, Miura S, Ariga H. et al. The natural history of maternal immunization against foetal platelet alloantigens. Transfus Med 2004; 14: 399-408
  • 4 Versiti. Human platelet antigen (HPA) database. 2024 https://www.versiti.org/hpa
  • 5 Sachs UJ, Wienzek-Lischka S, Duong Y. et al. Maternal antibodies against paternal class I human leukocyte antigens are not associated with foetal and neonatal alloimmune thrombocytopenia. Br J Haematol 2020; 189: 751-759
  • 6 Kiefel V, König C, Kroll H. et al. Platelet alloantibodies in transfused patients. Transfusion 2001; 41: 766-770
  • 7 Kiefel V. Platelet antibodies in immune thrombocytopenia and related conditions. J Lab Med 2020; 44: 273-284
  • 8 Borne von dem AEGK, Verheugt FWA, Oosterhof F. et al. A simple immunofluorescence test for the detection of platelet antibodies. Br J Haematol 1978; 39: 195-207
  • 9 Schneider W, Schnaidt M. The platelet adhesion immunofluorescence test: a modification of the platelet suspension immunofluorescence test. Blut 1981; 43: 389-392
  • 10 Socher I, Zwingel C, Santoso S. et al. Heterogeneity of HPA-3 alloantibodies: consequences for the diagnosis of alloimmune thrombocytopenic syndromes. Transfusion 2008; 48: 463-472
  • 11 Kelton JG, Vrbensky JR, Arnold DM. How do we diagnose immune thrombocytopenia in 2018?. Hematology (Am Soc Hematol Educ Program) 2018; 2018: 561-567
  • 12 Kiefel V. The MAIPA assay and its applications in immunohematology. Transfus Med 1992; 2: 181-188
  • 13 Santoso S, Kiefel V, Mueller-Eckhardt C.. Blood group A and B determinants are expressed on platelet glycoproteins IIa, IIIa, and Ib. Thromb Haemost 1991; 65: 196-201
  • 14 Alm J, Duong Y, Wienzek-Lischka S. et al. Anti-human platelet antigen-5b antibodies and fetal and neonatal alloimmune thrombocytopenia; incidental association or cause and effect?. Br J Haematol 2022; 98: 14-23
  • 15 Socher I, Andrei-Selmer C, Bein G. et al. Low-avidity HPA-1a alloantibodies in severe neonatal alloimmune thrombocytopenia are detectable with surface plasmon resonance technology. Transfusion 2009; 49: 943-952
  • 16 Brand A. Alloimmune platelet refractoriness: incidence declines, unresolved problems persist. Transfusion 2001; 41: 724-726
  • 17 Warner MN, Moore JC, Warkentin TE. et al. A prospective study of protein-specific assays used to investigate idiopathic thrombocytopenic purpura. Br J Haematol 1999; 104: 442-447
  • 18 Vrbensky JR, Moore JE, Arnold DM. et al. The sensitivity and specificity of platelet autoantibody testing in immune thrombocytopenia: a systematic review and meta-analysis of a diagnostic test. J Thromb Haemost 2019; 17: 787-794
  • 19 Vollenberg R, Jouni R, Norris PAA. et al. Glycoprotein V is a relevant immune target in patients with immune thrombocytopenia. Haematologica 2019; 104: 1237-1243